Abbott Laboratories logo

Abbott Laboratories (ABT)

NEW YORK STOCK EXCHANGE, INC. · Health Care

101,29 USD
+0.22%
Affidabilità dati: 100% · Alta
Apertura
100,81 USD
Chius. prec.
101,07 USD
Massimo
101,82 USD
Minimo
100,09 USD
Volume
Storico prezzi
Variazione periodo · 1M
-11.23%
114,10 USD → 101,29 USD
Massimo periodo
116,72 USD
Minimo periodo
100,09 USD
Buy
12
S.Buy
13
Buy
8
Hold
0
Sell
0
S.Sell

33 analisti: 12 Strong Buy · 13 Buy · 8 Hold · 0 Sell.

Target price analisti

120,26 USD
+18.7% Potenziale rialzo
Target minimo
103,00 USD
Target massimo
135,00 USD

Statistiche chiave

Fondamentali e dati di trading aggiornati. Fonte: Finnhub.

Valutazione
Capitalizzazione
175,27 Mld USD
P/E (TTM)
32.31
P/B
4.18
P/S (TTM)
3.76
EPS (TTM)
3,11 USD
Dividend yield
1.98%
Redditività
ROE
10.52%
ROA
5.56%
Margine lordo
56.78%
Margine netto
11.65%
Crescita
Crescita ricavi (YoY)
8.06%
Crescita EPS (YoY)
-61.21%
Solidità finanziaria
Debt / Equity
0.25
Current ratio
1.58
Dati di trading
Beta
0.55
Range 52 settimane
81,97 USD → 135,45 USD
Volume medio (10g)
9,55 Mln

Notizie sul titolo

Best Dividend Kings: September 2026

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.

SeekingAlpha26 set
NVST vs. ABT: Which Stock Is the Better Value Option?

NVST vs. ABT: Which Stock Is the Better Value Option?

Yahoo25 set
How To Build A $75,000 Dividend Portfolio With SCHD And 5 High-Yield Picks

Build a $75K dividend portfolio anchored by SCHD, enhanced with JEPI, VNG, and 8 quality stocks to boost yield, growth, and diversification—read now.

SeekingAlpha25 set
Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note

Abbott (ABT) concluded the recent trading session at $101.07, signifying a -2.34% move from its prior day's close.

Yahoo24 set
Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery

Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000. Information Technology was the main driver of […]

Yahoo24 set
TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher

Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "TDM Reagent Kit Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global TDM Reagent Kit Market, projected to reach USD 2.87 billion in 2026 and grow at a CAGR of 15.84% to USD 6.96 billion

Yahoo24 set
FDA Advisors Said It Should Approve the Grail Multicancer Blood Test

Grail stock rose 35% this week as the Food and Drug Administration considers the company’s cancer blood test.

Yahoo23 set
Is Abbott’s Digital Health Push and Formula Settlement Altering The Investment Case For Abbott (ABT)?

In recent weeks, Abbott and Berry Street announced an exclusive partnership that combines Abbott’s Lingo over-the-counter continuous glucose monitor with Berry Street’s insurance-covered virtual nutrition coaching, while Abbott’s Volt Pulsed Field Ablation System saw first clinical use in Canada and at UnityPoint Health – Trinity Heart Center in Illinois for treating atrial fibrillation. Alongside these developments, Abbott’s agreement to pay about US$385,000,000 to settle infant formula...

Yahoo23 set

Informazioni su Abbott Laboratories

Abbott Laboratories è quotata su NEW YORK STOCK EXCHANGE, INC. con il ticker ABT e opera nel settore Health Care. La capitalizzazione di mercato è di circa 175 miliardi di dollari.

Il consenso corrente degli analisti su ABT è Buy, calcolato su 33 giudizi: 12 Strong Buy, 13 Buy, 8 Hold, 0 Sell e 0 Strong Sell.

ABT tratta a un rapporto prezzo/utili (P/E) di 32,31. L'utile per azione degli ultimi dodici mesi è di 3,11 dollari. Il rendimento da dividendo è del 1,98%. Nelle ultime 52 settimane il titolo si è mosso tra 81,97 e 135,45 dollari.

Questa pagina raccoglie la quotazione in tempo reale di ABT, il grafico storico da 1 giorno a 5 anni, il target price medio degli analisti, i principali indicatori fondamentali (P/E, capitalizzazione, margini, crescita, indebitamento) e le ultime notizie sulla società. I prezzi sono consultabili in cinque valute.

Altri titoli Sanità e Farmaceutica →Cosa significano questi rating?

Solo scopo informativo. NON è consulenza finanziaria né raccomandazione di investimento (D.Lgs. 58/1998). I giudizi mostrati sono il consenso medio aggregato di analisti terzi via Finnhub. Vedi note legali. Note legali